Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the diagnostic performance of fully automated motion
corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected
first pass myocardial perfusion images in a cohort of patients with suspected ischemic heart
disease, using coronary angiography as the reference standard. It is expected that this
improved comprehensive protocol for cardiac MRI be accurate at detecting significant coronary
artery disease and may obviate the need for other more expensive and invasive diagnostic
tests currently used.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Northwestern University
Collaborators:
Astellas Pharma US, Inc. Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma